Bioventus Inc. (NASDAQ:BVS) Receives Average Recommendation of “Buy” from Analysts

Bioventus Inc. (NASDAQ:BVS) has been given an average recommendation of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $14.75.

Several analysts recently commented on the company. Barrington Research reaffirmed an “outperform” rating and set a $14.00 target price on shares of Bioventus in a report on Tuesday, June 30th. CJS Securities began coverage on shares of Bioventus in a research note on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price target on shares of Bioventus in a report on Tuesday, June 16th.

Hedge Funds Weigh In On Bioventus

Several large investors have recently bought and sold shares of the stock. Marshall Wace LLP raised its position in Bioventus by 0.4% during the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after acquiring an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Bioventus by 16.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after purchasing an additional 1,887 shares during the period. Deutsche Bank AG boosted its position in shares of Bioventus by 8.2% in the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock valued at $187,000 after acquiring an additional 1,908 shares during the period. Finally, Engineers Gate Manager LP grew its position in Bioventus by 6.0% in the 4th quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after purchasing an additional 3,909 shares during the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Stock Down 4.2%

Bioventus stock opened at $11.56 on Wednesday. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $12.30. The business’s 50-day simple moving average is $9.80 and its two-hundred day simple moving average is $9.05. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The company has a market cap of $965.66 million, a PE ratio of 28.20, a PEG ratio of 1.54 and a beta of 0.65.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The company had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities analysts anticipate that Bioventus will post 0.79 EPS for the current year.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.